Last reviewed · How we verify
BP-SCIG 20%
BP-SCIG 20% is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering immunoglobulin G (IgG) antibodies to patients with primary immunodeficiency.
BP-SCIG 20% is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering immunoglobulin G (IgG) antibodies to patients with primary immunodeficiency. Used for Primary immunodeficiency disorders requiring immunoglobulin replacement.
At a glance
| Generic name | BP-SCIG 20% |
|---|---|
| Sponsor | Biopharma Plasma LLC |
| Drug class | Immunoglobulin replacement therapy |
| Target | IgG (Immunoglobulin G) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This subcutaneous immunoglobulin (SCIg) formulation at 20% concentration replaces deficient or dysfunctional IgG antibodies in patients unable to produce adequate endogenous immunoglobulin. The therapy is administered subcutaneously, allowing for more frequent dosing intervals and improved quality of life compared to intravenous immunoglobulin (IVIg), while maintaining systemic IgG levels to prevent recurrent infections.
Approved indications
- Primary immunodeficiency disorders requiring immunoglobulin replacement
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Headache
- Fatigue
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |